ArticleGynecologic oncology reports2025

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma.

Michael Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.